Alpha Tau Medical Ltd.

NASDAQ:DRTS

Biotechnology

Healthcare
$12.01 +0.42%

+$0.04 today

Market cap
$1.11B
Beta
1.20
P/E (TTM)
-15.2
EPS (TTM)
-$0.63
52W Low $2.85High $11.62

Volume 0.64M

Average 0.69M

DRTS Net Income

Bottom-line profit, the starting point for calculating cash from operations.

Alpha Tau Medical Ltd.NASDAQ: DRTS

Net Income · Q4 FY2025 · quarter ended Dec 2025

Net income grows, but more slowly than its trailing trend

Q4 FY2025 net income of $12.14M (cash outflow) rose 28.1% year over year, behind the +34.3% change in trailing-twelve-month net income. Sequentially, it rose 3.9% from the prior quarter. Over 3 fiscal years it compounded at +8.1% a year.

Context

  • Net income grew in size in 2 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether net income reaches the consensus estimate from 2 analysts of -$53.07M (+24.5%) for the fiscal year ending Dec 2026, a slowdown from the +34.3% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterDec 2025
-$12.14M+3.9% QoQ
Last fiscal yearDec 2025
-$42.63M+34.3% YoY
LTMDec 2025
-$42.63M+34.3% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+28.1%+27.5%-0.5 pp
1 year+34.3%+24.5%-9.8 pp
3-year CAGR+8.1%-49.5%-57.6 pp
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the cash flow

Latest · FY2025
(42.63M) USD
Year-over-year change
-34.3%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How DRTS compares with its peers on the latest reported figures

  • DRTS's LTM Dec 2025 net income of $42.63M is the smallest of the 3 companies compared; the peer median is $87.43M.
  • Its year-over-year change of +34.3% is the 2nd highest of 3, against a peer median of +37.7%.
  • Over three fiscal years its annual growth of +8.1% compares with a peer median of +72.1%.
DRTS Competitors Peer median
Net Income for DRTS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CATXPerspective Therapeutics, Inc.LTM Mar 2026$111.13M +30.5%+91.6%17982.7%
AKTSAktis Oncology, Inc.FY2025$63.73M +44.9%+52.6%980.9%
DRTSAlpha Tau Medical Ltd.LTM Dec 2025$42.63M +34.3%+8.1%—
Peer median (excluding DRTS) $87.43M+37.7%+72.1%9481.8%

Competitors are the stored peer set for DRTS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(27.27M)(33.76M)(29.16M)(31.75M)(42.63M)
Depreciation & Amortization776K979K1.07M1.1M1.23M
Deferred Income Tax00000
Stock-Based Compensation812K6.75M7.93M9.92M0
Change in Working Capital585K(307K)2.49M1.17M2.29M
Accounts Receivables00000
Inventory00000
Accounts Payables239K220K1.14M965K337K
Other Working Capital346K(527K)1.35M203K1.95M
Other Non-Cash Items13.29M2.46M(293K)(219K)12.42M
Operating Cash Flow(11.81M)(23.88M)(17.96M)(19.78M)(26.68M)
Capital Expenditures(2.93M)(904K)(6.4M)(2.24M)(6.08M)
Acquisitions (Net)00000
Purchases of Investments000(125.08M)(70.49M)
Sales of Investments000148.19M55.98M
Other Investing Activities22.2M(89.03M)25.08M(103K)0
Investing Cash Flow19.27M(89.94M)18.68M20.77M(20.59M)
Debt Repayment00000
Common Stock Issued111K3.36M49K25K45.77M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities093.54M5.25M00
Financing Cash Flow111K96.91M5.3M25K45.77M
Effect of Forex Changes108K(258K)3.1M160K501K
Net Change in Cash7.68M(17.17M)9.12M1.17M(1M)
Free Cash Flow(14.74M)(24.78M)(24.36M)(22.02M)(32.76M)

Alpha Tau Medical Ltd.

NASDAQ:DRTS

Intrinsic Alpha fair value

Locked

Current Price

$12.01

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.